



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: April 4, 2008

To: NCCTG Primary Clinical Research Associates

From: Janis Wobschall
Protocol Development Coordinator

Re: N027D, A Phase I Study of CCI-779 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme

Due to the status change notice which reflects that approval of Addendum 3 is required prior to further patient enrollment, the pre-registration eligibility checklist has been revised as follows.

Addendum 3 dated March 28, 2008 IRB approved?

Yes. If Yes, Addendum 3 approval date (mm/dd/yyyy) ___/___/___

No. If No, End form, Addendum 3 IRB approval required.

If you have any questions, please feel free to contact me at 507/284-4852.

JW/dg
Enclosure